Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production
(Stuttgart) – Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
The ever increasing demand of high-quality biopharmaceutical therapies such as monoclonal antibodies requires more than ever highly efficient and robust production technologies. Simultaneously the digital transformation of the biopharmaceutical sector generates tremendous amounts of data from bioprocessing which represent an enormous value to be capitalized on.
Insilico’s solutions for predictive biomanufacturing are one of the key technologies to convert this value into higher quality therapies and to bring them faster to market. Insilico’s Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms in combination with flexible process models and artificial intelligence to create optimized production processes by computational simulations.
As a leading provider of high-quality medicines for nearly all therapeutic areas, Teva uses the most efficient and innovative technologies for best-in-class production of their therapeutic agents. “By complementing our process development capabilities with Insilico’s unique technology for digital bioprocess development we can accomplish robust and efficient production of our biologics pipeline faster”, says Jason Bock, VP of Biologics CMC at Teva. “Saving experimental efforts and time perfectly fits the accelerated timelines in clinical development that we are seeing now and even more in the future.”
Klaus Mauch, CEO of Insilico Biotechnology, adds: “We are proud to support Teva with our predictive solutions to speed-up the key steps in bioprocess development. The use of Insilico Digital Twins is able to transform the enormous wealth of process data generated every day into measurable improvements. We are absolutely convinced that this collaboration is a major step in predictive biomanufacturing and towards the future of biologics production.”
The collaboration will run for three years and will be based at Insilico's sites in Stuttgart, Germany and at Teva’s West Chester, PA, USA, location.
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico's unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany. Learn more at www.insilico-biotechnology.com
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com
Insilico Biotechnology AG
Dr. Daniel Horbelt | Business Development
T +49 711 460 594-14
F +49 711 460 594-10